207798-38-7

Basic information

• Product Name: 4-(4-FORMYL-PHENOXY)-PIPERIDINE-1-CARBOXYLIC ACID TERT-BUTYL ESTER
• Synonyms: 4-(4-FORMYL-PHENOXY)-PIPERIDINE-1-CARBOXYLIC ACID TERT-BUTYL ESTER;tert-butyl 4-(4-forMylphenoxy)piperidine-1-carboxylate
• CAS NO: 207798-38-7
• Molecular Formula: C₁₇H₂₃NO₄
• Molecular Weight: 305.36900
• Mol File: 207798-38-7.mol
• Article Data: 17

Chemical Properties

• Appearance: /
• CAS DataBase Reference: 4-(4-FORMYL-PHENOXY)-PIPERIDINE-1-CARBOXYLIC ACID TERT-BUTYL ESTER(CAS DataBase Reference)
• NIST Chemistry Reference: 4-(4-FORMYL-PHENOXY)-PIPERIDINE-1-CARBOXYLIC ACID TERT-BUTYL ESTER(207798-38-7)
• EPA Substance Registry System: 4-(4-FORMYL-PHENOXY)-PIPERIDINE-1-CARBOXYLIC ACID TERT-BUTYL ESTER(207798-38-7)

Safety Data

• Hazardous Substances Data: 207798-38-7(Hazardous Substances Data)

Usage

General Description

The chemical 4-(4-Formyl-phenoxy)-piperidine-1-carboxylic acid tert-butyl ester is a compound with a molecular formula of C18H23NO5. It is typically used as a building block in organic synthesis and pharmaceutical research. The tert-butyl ester group allows for increased stability and solubility of the compound, making it useful for various applications in the chemistry and pharmaceutical industries. This chemical may have potential uses in drug development and can serve as a precursor for the synthesis of various bioactive molecules.

Upstream product

• 123-08-0 4-hydroxy-benzaldehyde 
• 109384-19-2 t-butyl 4-hydroxy piperidine-1-carboxylate 
• 10465-78-8 diamide 
• 4143-61-7 diethyl diazodicarboxylate 
• 141699-59-4 1-(tert-butoxycarbonyl)piperidin-4-yl methanesulfonate 
• 118811-07-7 tert-butyl 4-(tosyloxy)piperidin-1-carboxylate 

Downstream Products

• 1190979-26-0 N-tert-butyl 4-(4-((4-(methylsulfonyl)piperazin-1-yl)methyl)phenoxy)piperidine-1-carboxylate 
• 943636-92-8 C₂₂H₂₇FN₂O₄ 
• 1404097-23-9 4-(1-nicotinoylpiperidin-4-yloxy)benzaldehyde 
• 1404097-22-8 4-(1-picolinoylpiperidin-4-yloxy)benzaldehyde 
• 1404097-26-2 4-(1-(5-chloropicolinoyl)piperidin-4-yloxy)benzaldehyde 
• 1404097-28-4 4-(1-(3-(trifluoromethyl)benzoyl)piperidin-4-yloxy)benzaldehyde 
• 1404097-29-5 4-(1-(3-fluoro-4-(trifluoromethyl)benzoyl)piperidin-4-yloxy)benzaldehyde 
• 1404097-30-8 4-(1-(4-(difluoromethoxy)benzoyl)piperidin-4-yloxy)benzaldehyde 
• 1404097-25-1 4-(1-(2-chloronicotinoyl)piperidin-4-yloxy)benzaldehyde 
• 1404097-31-9 4-(1-(4-nitropyridin-2-yl)piperidin-4-yloxy)benzaldehyde 
• 1404097-32-0 4-(1-(5-nitropyridin-2-yl)piperidin-4-yloxy)benzaldehyde 
• 1404097-33-1 2-(4-(4-formylphenoxy)piperidin-1-yl)nicotinonitrile 
• 1404097-34-2 4-(1-(3-(trifluoromethyl)pyridin-2-yl)piperidin-4-yloxy)benzaldehyde 
• 1404097-48-8 4-(1-(5-methylpyrazine-2-carbonyl)piperidin-4-yloxy)benzaldehyde 

Relevant articles and documents

Design, synthesis, and biological evaluation of 5-aminotetrahydroquinoline-based LSD1 inhibitors acting on Asp375

The abnormal expression of lysine-specific histone demethylase 1 (LSD1) is associated with different cancer types, and LSD1?inhibitory activity seems to have high therapeutic potential in cancer treatment. Here, we report the design, synthesis, and biochemical evaluation of novel 5-aminotetrahydroquinoline-based LSD1 inhibitors. Among them, compounds A6, A8, B1–B5, and C4 showed preferable inhibitory effects on LSD1, with IC50 = 0.19–0.82 μM. Several potent compounds were selected to evaluate their antiproliferative activity on A549 cells and MCF-7 cells with a high expression of LSD1. The potential binding modes of the compounds were revealed through molecular docking to rationalize the potency of compounds toward LSD1. Our data recognized that the 5-aminotetrahydroquinoline scaffold may serve as a starting point for developing potent LSD1 inhibitors for cancer therapy.

Tetrahydroquinoline derivative as well as preparation method and application thereof

The invention belongs to the field of drug synthesis, and provides a tetrahydroquinoline derivative shown as a general formula (I) and pharmaceutically acceptable salt, stereoisomers or prodrugs thereof, in which A, Ra, Rb, n, m and R are as described in

Thieno[3,2-b]pyrrole-5-carboxamides as New Reversible Inhibitors of Histone Lysine Demethylase KDM1A/LSD1. Part 2: Structure-Based Drug Design and Structure-Activity Relationship

The balance of methylation levels at histone H3 lysine 4 (H3K4) is regulated by KDM1A (LSD1). KDM1A is overexpressed in several tumor types, thus representing an emerging target for the development of novel cancer therapeutics. We have previously describe